NLM Digital Collections

Search

Start Over Subjects Medicare Part D -- economics ✖Remove constraint Subjects: Medicare Part D -- economics

2. Questionable billing for compounded topical drugs in Medicare Part D

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, August 2018
Subject(s):
Dermatologic Agents -- economics
Dermatologic Agents -- therapeutic use
Drug Compounding -- economics
Drug Utilization -- trends
Fraud
Insurance, Health, Reimbursement
Medicare Part D -- economics
Skin Cream -- economics
Administration, Topical
Dermatologic Agents -- adverse effects
Drug Compounding -- standards
Forecasting
Health Expenditures -- trends
Insurance Coverage
Skin Cream -- adverse effects
Humans
United States
United States. Department of Health and Human Services.
Centers for Medicare & Medicaid Services (U.S.)

4. High cost sharing and specialty drug initiation under Medicare Part D: a case study in patients with newly diagnosed chronic myeloid leukemia

Author(s):
Doshi, Jalpa A., author
Li, Pengxiang, author
Huo, Hairong, author
Pettit, Amy R., author
Kumar, Rishab, author
Weiss, Brendan M., author
Huntington, Scott F., author
Publication:
Philadelphia, PA : Leonard Davis Institute of Health Economics, 2016
Subject(s):
Cost Sharing
Drug Costs
Medicare Part D -- economics
Financing, Personal
Health Services Accessibility
Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- drug therapy
Protein Kinase Inhibitors -- economics
Protein Kinase Inhibitors -- therapeutic use
Protein-Tyrosine Kinases -- antagonists & inhibitors
Humans
United States

5. Impact of Medicare Advantage prescription drug plan star ratings on enrollment before and after implementation of quality-related bonus payments in 2012

Author(s):
Li, Pengxiang, author
Doshi, Jalpa A., author
Publication:
Philadelphia, PA : Leonard Davis Institute of Health Economics, May 2016
Subject(s):
Insurance, Pharmaceutical Services -- economics
Medicare Part C -- economics
Medicare Part C -- utilization
Quality of Health Care
Reimbursement, Incentive
Longitudinal Studies
Medicare Part D -- economics
Humans
United States
Centers for Medicare & Medicaid Services (U.S.)

8. Medicare Part D: a first look at prescription drug plans in 2019

Author(s):
Cubanski, Juliette, author
Damico, Anthony, author
Neuman, Tricia, author
Publication:
San Francisco, CA : Henry J. Kaiser Family Foundation, October 2018
Subject(s):
Medicare Part D -- economics
Medicare Part D -- statistics & numerical data
Cost Sharing
Deductibles and Coinsurance
Insurance Benefits
Insurance, Pharmaceutical Services -- economics
Insurance, Pharmaceutical Services -- statistics & numerical data
Humans
United States

10. Federal mandatory spending for means-tested programs, 2008 to 2028

Publication:
Washington, D.C. : Congressional Budget Office, June 2018
Subject(s):
Federal Government
Health Expenditures -- statistics & numerical data
Health Expenditures -- trends
Medicaid -- economics
Medicare -- economics
Cost Sharing
Food Assistance -- economics
Forecasting
Mandatory Programs -- economics
Medicare Part D -- economics
Humans
United States
United States.

11. Prices for and spending on specialty drugs in Medicare Part D and Medicaid: an in-depth analysis

Author(s):
Anderson-Cook, Anna, author
Maeda, Jared, author
Nelson, Lyle, author
Publication:
[Washington, DC] : Congressional Budget Office, March 2019
Subject(s):
Health Expenditures -- statistics & numerical data
Health Expenditures -- trends
Medicaid -- economics
Medicare Part D -- economics
Prescription Drugs -- economics
Drug Costs
Economics, Pharmaceutical -- trends
Forecasting
Medicaid -- trends
Medicare Part D -- trends
Orphan Drug Production -- economics
Humans
United States

12. Prices for and spending on specialty drugs in Medicare Part D and Medicaid

Publication:
[Washington, DC] : Congressional Budget Office, March 2019
Subject(s):
Health Expenditures -- statistics & numerical data
Health Expenditures -- trends
Medicaid -- economics
Medicare Part D -- economics
Prescription Drugs -- economics
Drug Costs
Economics, Pharmaceutical -- trends
Forecasting
Medicaid -- trends
Medicare Part D -- trends
Orphan Drug Production -- economics
Humans
United States

14. Does Medicare Part D protect the elderly from financial risk?

Author(s):
Englehardt, Gary V., author
Gruber, Jonathan, author
Publication:
Chestnut Hill, MA : Center for Retirement Research at Boston College, June 2011
Subject(s):
Financing, Personal
Health Services for the Aged -- economics
Insurance Coverage -- economics
Medicare Part D -- economics
Risk Sharing, Financial
Aged
Drug Costs
Forecasting
Health Care Surveys
Health Expenditures -- statistics & numerical data
Insurance Coverage -- statistics & numerical data
Medicare Part D -- statistics & numerical data
Medicare Part D -- trends
Prescription Drugs -- economics
Socioeconomic Factors
Humans
United States

15. Medicare Part D: a first look at prescription drug plans in 2018

Author(s):
Cubanski, Juliette, author
Damico, Anthony, author
Hoadley, Jack, author
Orgera, Kendal, author
Neuman, Tricia, author
Publication:
Menlo Park, CA : Henry J. Kaiser Family Foundation, October 2017
Subject(s):
Medicare Part C -- economics
Medicare Part C -- statistics & numerical data
Medicare Part C -- trends
Medicare Part D -- economics
Medicare Part D -- statistics & numerical data
Medicare Part D -- trends
Cost Sharing -- statistics & numerical data
Deductibles and Coinsurance -- statistics & numerical data
Forecasting
Humans
United States

17. No limit: Medicare Part D enrollees exposed to high out-of-pocket drug costs without a hard cap on spending

Author(s):
Cubanski, Juliette, author
Neuman, Tricia, author
Orgera, Kendal, author
Damico, Anthony, author
Publication:
Menlo Park, CA : Henry J. Kaiser Family Foundation, November 2017
Subject(s):
Drug Costs
Financing, Personal
Health Expenditures
Medicare Part D -- economics
Medicare Part D -- trends
Chronic Disease -- drug therapy
Chronic Disease -- economics
Demography
Hepatitis C -- drug therapy
Leukemia -- drug therapy
Lymphoma -- drug therapy
Poverty
Humans
United States

18. The Medicare drug benefit coverage gap: the basics

Publication:
Washington, D.C. : George Washington University, [2011]
Subject(s):
Insurance Coverage -- economics
Insurance Coverage -- legislation & jurisprudence
Insurance, Pharmaceutical Services -- economics
Insurance, Pharmaceutical Services -- legislation & jurisprudence
Medicare Part D -- economics
Medicare Part D -- legislation & jurisprudence
Drug Costs -- statistics & numerical data
Drug Prescriptions -- economics
Financing, Personal -- economics
Financing, Personal -- legislation & jurisprudence
Humans
United States

19. The economic burden of out-of-pocket medical expenditures before and after implementation of the Medicare prescription drug program

Author(s):
Akincigil, Ayse, author
Zurlo, Karen, author
Publication:
Chestnut Hill, MA : Center for Retirement Research at Boston College, November 2015
Subject(s):
Financing, Personal
Health Expenditures -- statistics & numerical data
Dual MEDICAID MEDICARE Eligibility
Insurance, Health -- economics
Medicaid -- economics
Medicare -- economics
Medicare Part D -- economics
Humans
United States

20. How much does out-of-pocket medical spending eat away at retirement income?

Author(s):
McInerney, Melissa, author
Rutledge, Matthew S., author
King, Sara Ellen., author
Publication:
Chestnut Hill, MA : Center for Retirement Research at Boston College, October 2017
Subject(s):
Cost Sharing -- economics
Financing, Personal
Medicare Part D -- economics
Retirement -- economics
Social Security -- economics
Aged
Cost Sharing -- trends
Financing, Personal -- trends
Forecasting
Medicare Part D -- trends
Retirement -- trends
Social Security -- trends
Humans
United States

21. Part D plans generally include drugs commonly used by dual eligibles: 2017

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, June 2017
Subject(s):
Dual MEDICAID MEDICARE Eligibility
Formularies as Topic
Insurance Coverage
Medicare Part D -- statistics & numerical data
Drug Utilization
Medicare Part D -- economics
Humans
United States
United States. Department of Health and Human Services.
United States.

25. Prescription opioids: Medicare should expand oversight efforts to reduce the risk of harm : testimony before the Subcommittee on Oversight, Committee on Ways and Means, House of Representatives

Publication:
Washington, DC : United States Government Accountability Office, January 17, 2018
Subject(s):
Drug and Narcotic Control
Inappropriate Prescribing -- prevention & control
Medicare Part D -- statistics & numerical data
Opioid-Related Disorders
Prescription Drug Misuse -- statistics & numerical data
Analgesics, Opioid -- adverse effects
Fraud -- prevention & control
Government Regulation
Inappropriate Prescribing -- statistics & numerical data
Medicare Part D -- economics
Humans
United States
Centers for Medicare & Medicaid Services (U.S.)

28. Rx Watchdog report: comparative measures of price change for prescription drugs and other goods

Publication:
Washington, D.C. : AARP Public Policy Institute, c2009
Subject(s):
Drug Costs -- statistics & numerical data
Health Expenditures -- statistics & numerical data
Medicare Part D -- economics
Prescription Drugs -- economics
Drug Costs -- trends
Drugs, Generic -- economics
Forecasting
Health Expenditures -- trends
Inflation, Economic
Humans
United States

29. Resource tests and eligibility for federal assistance programs: effects of current rules and options for change

Publication:
Washington, D.C. : AARP Public Policy Institute, c2010
Subject(s):
Eligibility Determination
Government Programs -- economics
Income
Selection Bias
Data Collection -- methods
Medicare -- statistics & numerical data
Medicare Part D -- economics
Poverty -- economics
Public Assistance -- economics
Social Security -- economics
Socioeconomic Factors
Humans
United States

32. Rx price watch report: trends in retail prices of specialty prescription drugs widely used by Medicare beneficiaries : 2005 to 2009

Publication:
Washington, D.C. : AARP Public Policy Institute, c2012
Subject(s):
Drug Costs -- trends
Medicare Part D -- economics
Prescription Drugs -- economics
Drug Costs -- statistics & numerical data
Drugs, Generic -- economics
Forecasting
Pharmaceutical Preparations -- economics
Humans
United States

34. Inflation Reduction Act research series: Medicare Part D enrollee savings from elimination of vaccine cost-sharing

Author(s):
Sayed, Bisma A., author
Finegold, Kenneth, 1957- author
Ashok, Kaavya, author
Schutz, Sarah, author
De Lew, Nancy, author
Sheingold, Steven, author
Sommers, Benjamin D., author
Publication:
Washington, D.C. : Office of the Assistant Secretary for Planning and Evaluation, Office of Health Policy, March 15, 2023
Subject(s):
Cost Savings
Cost Sharing -- economics
Medicare Part D -- economics
Vaccines -- economics
United States
United States. Inflation Reduction Act.

35. Capping Medicare beneficiary Part D spending at $2,000: who would it help and how much?

Author(s):
Gangopadhyaya, Anuj, author
Garrett, Bowen, author
Publication:
Washington, DC : Urban Institute, March 2022
Subject(s):
Health Equity -- economics
Health Expenditures -- statistics & numerical data
Health Policy
Medicare Part D -- economics
Prescription Fees -- legislation & jurisprudence
Social Mobility
United States

36. Summary of recent and proposed changes to Medicare prescription drug coverage and reimbursement

Author(s):
Cubanski, Juliette, author
Publication:
Menlo Park, CA : Henry J. Kaiser Family Foundation, February 2018
Subject(s):
Medicare Part B -- economics
Medicare Part D -- economics
Prescription Drugs -- economics
Formularies as Topic
Insurance, Health, Reimbursement -- economics
Medicare Part B -- legislation & jurisprudence
Medicare Part D -- legislation & jurisprudence
Humans
United States

37. An illustrative analysis of Medicare Options Compare: what's there and what's not

Publication:
Washington, D.C. : AARP Public Policy Institute, c2009
Subject(s):
Choice Behavior
Internet
Managed Care Programs -- economics
Medicare -- economics
Access to Information
Cost Sharing
Health Maintenance Organizations -- economics
Insurance Coverage
Medicare Part D -- economics
Patient Satisfaction
Preferred Provider Organizations -- economics
Humans
United States
Centers for Medicare & Medicaid Services (U.S.)

41. Rx Price Watch report: retail prices for widely used brand name drugs increase considerably prior to generic competition

Publication:
Washington, D.C. : AARP Public Policy Institute, c2011
Subject(s):
Drug Costs -- trends
Drug Therapy -- statistics & numerical data
Economic Competition
Pharmaceutical Preparations -- economics
Drug Approval
Drug Costs -- statistics & numerical data
Forecasting
Medicare Part D -- economics
Patents as Topic
Humans
United States

43. Prescription drugs: Department of Veterans Affairs paid about half as much as Medicare Part D for selected drugs in 2017 : report to the Ranking Member, Committee on the Budget, U.S. Senate

Publication:
Washington, DC : United States Government Accountability Office, December 2020
Subject(s):
Costs and Cost Analysis -- statistics & numerical data
Drug Costs -- statistics & numerical data
Government Regulation
Medicare Part D -- economics
United States
United States. Department of Veterans Affairs

46. A comparison of brand-name drug prices among selected federal programs

Author(s):
Baker, Colin, author
Laughery, Scott, author
Patel, Yash, author
Publication:
[Washington, DC] : Congressional Budget Office, February 2021
Subject(s):
Drug Costs -- statistics & numerical data
Government Programs -- economics
Medicaid -- economics
Federal Government
Medicare Part D -- economics
Prescription Drugs -- economics
United States
United States. Department of Defense.
United States. Department of Veterans Affairs.

48. High-expenditure Medicare drugs often qualified for Orphan Drug Act incentives designed to encourage the development of treatments for rare diseases

Publication:
Washington, D.C. : U.S. Department of Health and Human Services, Office of Inspector General, September 2021
Subject(s):
Drug Development -- legislation & jurisprudence
Government Regulation
Medicare Part B -- economics
Medicare Part D -- economics
Orphan Drug Production -- economics
United States
United States. Department of Health and Human Services

49. Medicare Part D: a first look at plan offerings in 2016

Author(s):
Hoadley, Jack, author
Cubanski, Juliette, author
Neuman, Tricia, author
Publication:
Menlo Park, CA : Henry J. Kaiser Family Foundation, October 2015
Subject(s):
Insurance Benefits -- economics
Insurance Benefits -- statistics & numerical data
Insurance Coverage -- economics
Insurance Coverage -- statistics & numerical data
Insurance, Pharmaceutical Services -- economics
Insurance, Pharmaceutical Services -- statistics & numerical data
Medicare Part D -- economics
Medicare Part D -- statistics & numerical data
United States

52. Catastrophic coverage in the Medicare Part D drug benefit: which beneficiaries need it and how much are they spending?

Author(s):
Sen, Aditi P., author
Parasrampuria, Sonal, author
Anderson, Kelly E., author
Anderson, Gerard, author
Publication:
[New York, N.Y.] : The Commonwealth Fund, September 2020
Subject(s):
Health Expenditures -- statistics & numerical data
Medicare Part D -- economics
Financing, Personal
United States

53. Medicare Part D and beneficiaries could realize significant spending reductions with increased biosimilar use

Publication:
Washington, D.C. : U.S. Department of Health and Human Services, Office of Inspector General, March 2022
Subject(s):
Biosimilar Pharmaceuticals
Drug Costs -- legislation & jurisprudence
Government Regulation
Medicare Part D -- economics
United States
United States. Department of Health and Human Services
Centers for Medicare & Medicaid Services (U.S.)

54. The effect of Medicare Part D on evergreening, generic entry, and drug prices

Author(s):
Sanzenbacher, Geoffrey T., author
Wettstein, Gal, author
Publication:
Chestnut Hill, MA : Center for Retirement Research at Boston College, May 2019
Subject(s):
Drug Costs
Drugs, Generic -- economics
Medicare Part D -- economics
Patents as Topic
Aged
Drug Industry -- economics
Economics, Pharmaceutical
Humans
United States
United States. Food and Drug Administration.
Medical Expenditure Panel Survey (U.S.)

55. Do states adjust Medicaid enrollment in response to capitation rates?: evidence from the Medicare Part D clawback

Author(s):
Quinby, Laura D., author
Wettstein, Gal, author
Publication:
Chestnut Hill, MA : Center for Retirement Research at Boston College, June 2019
Subject(s):
Capitation Fee
Dual MEDICAID MEDICARE Eligibility
Medicaid -- economics
Medicare -- economics
Medicare Part D -- economics
Federal Government
Forecasting
Health Expenditures -- trends
State Government
Humans
United States

56. Payment reform

Publication:
[Toronto, Ontario] : Thomson Reuters, 23-December-2019
Subject(s):
Health Care Reform -- economics
Health Care Reform -- legislation & jurisprudence
Insurance, Health, Reimbursement -- legislation & jurisprudence
Emergency Medical Services -- economics
Federal Government
Home Care Services -- economics
Medicare Part D -- economics
Medical Oncology -- economics
Patient Readmission
Prenatal Care -- economics
Reimbursement Mechanisms
Social Determinants of Health
State Government
Transportation of Patients
Value-Based Purchasing
Humans
United States
United States. Department of Health and Human Services.
Centers for Medicare & Medicaid Services (U.S.)

57. Cost savings

Author(s):
Steiner, David J., author
Publication:
[Toronto, Ontario] : Thomson Reuters, 23-December-2019
Subject(s):
Cost Control -- legislation & jurisprudence
Cost Savings
Drug Costs -- legislation & jurisprudence
Economics, Pharmaceutical
Legislation, Drug
Access to Information
Biosimilar Pharmaceuticals
Commerce
Conflict of Interest
Drug Industry
Insurance, Pharmaceutical Services
Managed Care Programs
Medicaid -- economics
Medicare Part D -- economics
Patents as Topic
State Government
Humans
United States

58. Medicare Part D

Author(s):
Steiner, David J., author
Publication:
[Toronto, Ontario] : Thomson Reuters, 23-December-2019
Subject(s):
Drug Costs
Medicare Part D -- economics
Medicare Part D -- legislation & jurisprudence
Biosimilar Pharmaceuticals -- economics
Cost Control -- legislation & jurisprudence
Drugs, Generic -- economics
Economics, Pharmaceutical
Financing, Personal
Fraud
Legislation, Drug
Medicare Part C
Opioid-Related Disorders
Humans
United States
United States. Department of Health and Human Services.
Centers for Medicare & Medicaid Services (U.S.)

59. Part D plans generally include drugs commonly used by dual eligibles: 2019

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, June 2019
Subject(s):
Dual MEDICAID MEDICARE Eligibility
Formularies as Topic
Insurance Coverage
Medicare Part D -- economics
Insurance, Pharmaceutical Services -- economics
Medicaid -- economics
Medicare -- economics
Humans
United States
United States.
Centers for Medicare & Medicaid Services (U.S.)

60. Rebates for brand-name drugs in Part D substantially reduced the growth in spending from 2011 to 2015

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, September 2019
Subject(s):
Drug Costs -- statistics & numerical data
Drug Costs -- trends
Insurance, Health, Reimbursement -- statistics & numerical data
Insurance, Health, Reimbursement -- trends
Medicare Part D -- economics
Medicare Part D -- statistics & numerical data
Medicare Part D -- trends
Economics, Pharmaceutical -- statistics & numerical data
Economics, Pharmaceutical -- trends
Forecasting
Prescription Drugs -- economics
Humans
United States

61. Medicare spending trends 2010-2016: increase in prescription drug spending more than offsets lower beneficiary costs for other services

Author(s):
Schoen, Cathy, author
Willink, Amber, author
Davis, Karen, author
Publication:
[New York, N.Y.] : The Commonwealth Fund, November 2019
Subject(s):
Financing, Personal -- trends
Health Expenditures -- trends
Medicare -- economics
Medicare -- trends
Drug Costs -- trends
Forecasting
Medicare Part D -- economics
Medicare Part D -- trends
Poverty
Humans
United States

64. Medicare Part D enrollee out-of-pocket spending: recent trends and projected impacts of the Inflation Reduction Act

Author(s):
Sayed, Bisma A., author
Finegold, Kenneth, 1957- author
Olsen, T. Anders, author
Ashok, Kaavya, author
Shutz, Sarah, author
Sheingold, Steven, author
De Lew, Nancy, author
Sommers, Benjamin D., author
Publication:
Washington, D.C. : Assistant Secretary for Planning and Evaluation, Office of Health Policy, July 7, 2023
Subject(s):
Health Expenditures -- statistics & numerical data
Health Expenditures -- trends
Medicare Part D -- economics
Medicare Part D -- statistics & numerical data
State Government
United States
United States.

65. Medicare Part D: CMS should monitor effects of rebates on plan formularies and beneficiary spending : report to congressional requesters

Publication:
Washington, DC : United States Government Accountability Office, September 2023
Subject(s):
Drug Costs
Government Regulation
Legislation, Medical
Medicare Part D -- economics
Medicare Part D -- organization & administration
Prescription Fees
United States
Centers for Medicare & Medicaid Services (U.S.)

66. Medicare Part D: CMS should monitor effects of rebates on drug coverage and spending : testimony before the Subcommittee on Health, Committee on Energy and Commerce, House of Representatives

Publication:
Washington, DC : United States Government Accountability Office, September 19, 2023
Subject(s):
Government Regulation
Legislation, Medical
Medicare Part D -- economics
Medicare Part D -- organization & administration
Prescription Drugs -- economics
United States

67. The risk of misuse and diversion of buprenorphine for opioid use disorder in Medicare Part D continues to appear low: 2022

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, November 2023
Subject(s):
Buprenorphine
Drug Users -- statistics & numerical data
Government Regulation
Medicare Part D -- economics
Opiate Substitution Treatment
Opioid-Related Disorders -- drug therapy
Prescription Drug Diversion -- statistics & numerical data
United States